-
NMPA Launches ‘Medical Service Price Items’ Column with Comprehensive Sub-Sections
•
The National Medical Products Administration (NMPA) has taken a significant step towards enhancing transparency in the medical sector by launching a new “Medical Service Price Items” column on its official website. This initiative is designed to provide a centralized resource for stakeholders, including patients, healthcare providers, and policymakers, and is…
-
NHSA and MoF Announce Medical Insurance Fund Prepayment Initiative to Aid Healthcare Institutions
•
The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly issued a notification regarding the implementation of a medical insurance fund prepayment initiative. This program is designed to provide financial relief to designated medical institutions by prepaying a portion of the medical insurance fund, thereby easing…
-
NHSA and MCA Boost Medical Assistance with Enhanced Information Sharing Measures
•
The National Healthcare Security Administration (NHSA) and the Ministry of Civil Affairs (MCA) have jointly issued a notification with the goal of enhancing the information sharing process for medical assistance recipients. This initiative is designed to address the issue of delayed inter-departmental information sharing, which impacts the timely disbursement and…
-
China’s NHSA Sets October Dates for National Reimbursement Drug List Negotiations and Price Bidding
•
The National Healthcare Security Administration (NHSA) has announced that the one-site negotiation and price bidding for the adjustment of the National Reimbursement Drug List (NRDL) will be conducted from October 27 to 30 in Beijing, with results anticipated to be released next month. The updated version of the NRDL is…
-
China’s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List
•
According to the Economic Observer, an independent Chinese weekly newsletter, a series of discussions preceding the National Reimbursement Drug List (NRDL) price negotiation occurred from October 16 to 18. These pre-negotiation talks, which serve as one-on-one communications prior to the formal negotiation process, were divided into three groups this year.…
-
NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud
•
The National Healthcare Security Administration (NHSA) has issued a notification aimed at standardizing the management of purchasing drugs from the National Reimbursement Drug List (NRDL) outside hospital settings with a prescription. This initiative is intended to enhance oversight of the entire prescription circulation process and combat fraudulent prescriptions and insurance…
-
China’s National Healthcare Security Administration Issues Draft Guidelines for Long-Term Care Insurance
•
The National Healthcare Security Administration (NHSA) has released the “Draft Technical Guidelines for the Preparation of Biosimilar Drug Labels” along with several other documents to guide the construction of the long-term care insurance (LTCI) system in China. The “Interim Measures” will come into effect on May 1, 2024, and aim…
-
China Unveils Medical Insurance Eligibility Management System for Designated Healthcare Personnel
•
The National Healthcare Security Administration (NHSA), National Health Commission, and National Medical Products Administration (NMPA) have jointly issued guidelines aimed at establishing a medical insurance payment eligibility management system for personnel at designated medical institutions. This initiative pertains to individuals at such institutions who are involved with the use of…
-
NHSA Concludes 2024 NRDL Review, Announces Submission Deadlines for Drug Manufacturers
•
The National Healthcare Security Administration (NHSA) has declared the completion of the expert review process for the 2024 National Reimbursement Drug List (NRDL) adjustments. The NHSA has directed relevant pharmaceutical companies to check the review outcomes on its official website, fuwu.nhsa.gov.cn. Manufacturers of drugs that have received review outcomes classified…
-
China’s NHSA and MOF Issue Notices to Enhance Cross-Regional Medical Treatment Direct Settlement
•
The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MOF) have issued two key notices aimed at enhancing the healthcare system in China. The first, ‘Notice on Further Strengthening the Management Service of Direct Settlement for Medical Treatment Incurred in Other Regions,’ outlines several measures to improve the…
-
China’s NHSA Proposes New Guidelines to Enhance Oversight of Medical Insurance Funds
•
The National Healthcare Security Administration (NHSA) has unveiled a draft of the “Guiding Opinions on Strengthening Management of Social Supervisors of Medical Insurance Funds” for public consultation. This initiative aims to engage a broad spectrum of societal actors in the oversight of Basic Medical Insurance (BMI) funds, ensuring the integrity…
-
China to Enhance Basic Medical Insurance Coverage for Residents in 2024 with Increased Subsidies and Personal Payments
•
The National Healthcare Security Administration (NHSA), in conjunction with the Ministry of Finance and State Taxation Administration, has issued a notification with the goal of enhancing the basic medical insurance coverage for urban and rural residents in 2024. The notification emphasizes the need to continuously increase funding for residents’ medical…
-
NHSA Flags Concerns Over Pricing of MicroPort’s Castor Aortic Stent Graft System
•
BEIJING—The National Healthcare Security Administration (NHSA) has issued an open letter expressing concerns over the pricing of Shanghai MicroPort Endovascular MedTech Co., Ltd’s (SHA: 688016) Castor aortic stent graft and delivery system. The NHSA’s inquiry comes after reports from the public highlighted the artificially high prices of the product. According…
-
NHSA Preliminary Review Identifies Potential NRDL Additions, Including Novel Therapies and ADCs
•
The National Healthcare Security Administration (NHSA) has released a preliminary list of drugs that have passed the initial formal review stage for potential inclusion in the National Reimbursement Drug List (NRDL) for this year, with a public feedback period open until August 18, 2024. The NHSA received a total of…
-
China’s NHSA and NHC to Integrate Village Clinics into Basic Medical Insurance System
•
The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) of China have issued a joint notification to incorporate village clinics into the Basic Medical Insurance (BMI) system, marking a significant step towards enhancing healthcare funding support for rural medical facilities. The initiative is designed to bolster the…
-
NHSA Report: China’s Medical Insurance Fund Records Significant Growth and Savings in 2023
•
The National Healthcare Security Administration (NHSA) has released its comprehensive annual statistical report for the national medical and healthcare development in 2023. The report highlights that the Basic Medical Insurance (BMI) fund recorded an income of RMB 3.35 trillion, with expenditures amounting to RMB 2.82 trillion over the year. In…
-
China’s NHSA Updates DRG/DIP Payment Reform Program with New Exclusion Mechanisms and Timelines
•
The National Healthcare Security Administration (NHSA) in China has issued a notification outlining several updates to the Diagnosis Related Groups (DRG)/Diagnosis-Intervention Packet (DIP) hospital payment reform program. The new guidance mandates that regions which have not yet initiated DRG/DIP payment reforms must adopt the 2.0 version immediately, while regions that…
-
NHSA Mandates Standardized Online Procurement for Injectable Drugs to Ensure Pricing Transparency
•
The National Healthcare Security Administration (NHSA) has issued a directive to standardize the procurement process for injectable drugs, requiring that the smallest on-market preparation unit be used for online purchases. This move is aimed at achieving pricing transparency and reducing price disparities caused by variations in packaging quantities and conversion…
-
LG Chem and Yifan Pharmaceutical Launch Hyruan ONE for Knee Osteoarthritis in China
•
LG Chem, a leading chemical company based in South Korea, and Yifan Pharmaceutical Co., Ltd (SHE: 002019) from China, have announced the market launch of Hyruan ONE (sodium hyaluronate) in China for the treatment of knee osteoarthritis. Hyruan ONE, originally developed by LG Chem, is a single-dose preparation designed to…
-
China’s NHSA Releases 2024 National Reimbursement Drug List Adjustment Plan
•
The National Healthcare Security Administration (NHSA) has published the National Reimbursement Drug List (2024) adjustment work plan, along with filing guidelines. The guidelines are largely consistent with the previous year’s National Reimbursement Drug List (NRDL) update. Eligibility for consideration for NRDL inclusion is extended to all drugs that have received…
-
NHSA Seeks Public Input on National Reimbursement Drug List Adjustments
•
The National Healthcare Security Administration (NHSA) has unveiled the adjustment plan for the National Reimbursement Drug List (NRDL) for the current year and is soliciting public feedback until June 19, 2024. The NHSA has outlined the criteria for drug inclusion, which aligns with previous years’ requirements. Eligibility for inclusion on…
-
China’s NHSA and MoF Plan Expansion of Long-term Care Insurance System Pilot Program
•
The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly issued a set of guiding opinions on “Expanding the Pilot Program for the Long-term Care Insurance System.” The document emphasizes that the long-term care insurance system should prioritize addressing the long-term care security needs of severely…
-
Shenzhen’s Draft Proposal for VBP Drug Procurement and Medical Insurance Fund Management Released
•
The Healthcare Security Administration (HSA) Bureau of the Shenzhen municipality has released a “Shenzhen Drug Volume-based Procurement (VBP) Medical Insurance Fund Balance Retention Management Measures (draft proposal)” and is soliciting public feedback until June 13, 2024. This document will apply to all VBP drugs with purchase agreements expiring this year…
-
NMPA Announces Digitalization of Medical Device Regulatory Documents
•
The National Medical Products Administration (NMPA) has announced a transition to digitalize regulatory documentation for medical devices. Effective June 1, 2024, this digitalization will apply to scenarios where medical devices are not approved for marketing, market filings are terminated for review, and product inserts are not approved for changes, among…
-
China’s NHSA Launches New Procedures for Drug Catalogue Attribution Identification
•
The National Healthcare Security Administration (NHSA) has issued the “Procedures for Identification of Drug and Medical Insurance Catalogue Attribution (Trial)”, which takes effect immediately. The program is designed to address instances where a drug’s name or dosage form may not align with the National Reimbursement Drug List (NRDL) due to…
-
China Unveils Comprehensive Plan to Tackle Unhealthy Practices in Pharma and Healthcare
•
The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA), and a total of 14 ministries have issued the “Key Points for Correcting Unhealthy Practices in the Field of Pharmaceutical Procurement and Sales and Medical Services in 2024.” The document aims to address key personnel…
-
Beijing Unveils Action Plan to Boost Pharmaceutical and Health Industry by 2026
•
The Beijing People’s Government has issued an “Action Plan” outlining measures and targets to “Accelerate Collaborative Innovation in Medicine and Health” over a three-year period from 2024 to 2026. Many of these measures were previously outlined in a draft document reported in April 2024. The plan sets an ambitious goal…
-
China’s NHSA Aims to Boost Medical Insurance Reform with Sanming Model
•
The National Healthcare Security Administration (NHSA) has issued a notification aimed at promoting the medical reform experiences of Sanming, with a focus on intensifying medical insurance reform and service management. The key tasks outlined in the notification are as follows: Galvanize Drug and Consumables VBP Reforms:The bureau will persist in…
-
NHSA Unveils 2024 Medical Procurement Overhaul, Aiming for Synergy Between National and Provincial Levels
•
The National Healthcare Security Administration (NHSA) has issued a notification detailing plans to enhance the medical centralized procurement process in 2024. The goals include strengthening local procurement alliances and achieving a coordinated procurement strategy between national and local levels. For the national volume-based procurement (VBP), new batches will be led…
-
China Launches Nationwide Unannounced Inspections of Medical Insurance Funds
•
An inaugural meeting for the first batch of unannounced medical insurance fund inspections was conducted in Zhengzhou, Henan province, marking the commencement of a nationwide, cross-provincial initiative. The team is tasked with reviewing the utilization and management of medical insurance funds, along with the establishment and enforcement of pertinent internal…
-
China Launches Unannounced Inspections on Medical Insurance Funds, Targets Fraud and Mismanagement
•
The National Healthcare Security Administration (NHSA), National Health Commission (NHC), along with two other bureaus, have jointly issued a notification to commence unannounced inspections of medical insurance funds for the period from January 1, 2022, to December 31, 2023. The inspections will concentrate on the utilization and management of medical…
-
China’s Health Authorities Investigate Alleged Price Manipulation in Pharma Procurement Tenders
•
Chinese health regulators are delving into allegations of irregular pricing practices during the national volume-based procurement (VBP) tenders for several pharmaceutical products. A joint statement issued by the National Drug Alliance Procurement Office and the Shanghai Pharmaceutical Centralized Bidding Procurement Management Office cited public complaints regarding the bidding and pricing…
-
China Unveils 2024 Plan to Combat Fraud in Medical Insurance Funds
•
The National Healthcare Security Administration (NHSA) of China, in conjunction with the Supreme People’s Court, the Supreme People’s Procuratorate, the Ministry of Public Security, the Ministry of Finance, and the National Health Commission, has unveiled the “2024 Special Work Plan for the Rectification of Illegal and Non-compliant Issues Related to…
-
Chinese Authorities Launch Special Plan to Rectify Medical Insurance Fraud and Non-Compliance
•
The National Healthcare Security Administration (NHSA) of China, in collaboration with the Supreme People’s Court, Supreme People’s Procuratorate, Ministry of Public Security, Ministry of Finance, and National Health Commission, has jointly issued the “2024 Special Work Plan for the Rectification of Illegal and Non-compliant Issues Related to Medical Insurance Funds.”…
-
NHSA Reports 2023 Milestones in Basic Medical Insurance Participation and Financials
•
The National Healthcare Security Administration (NHSA) has published its annual “Healthcare Security Development Statistical Bulletin” for 2023, revealing significant developments in China’s Basic Medical Insurance (BMI) landscape. By the end of 2023, participation in various BMI schemes reached 1.33 billion, maintaining a coverage rate of over 95%. Specifically, 370.94 million…
-
China Expands Medical Service Pricing Reform with Three Additional Pilot Provinces
•
The National Healthcare Security Administration (NHSA) has announced an expansion of its medical services pricing reform initiative, designating Inner Mongolia, Zhejiang, and Sichuan provinces as pilot regions to further deepen the reform of medical service pricing. These provinces join the existing pilot cities of Tangshan in Hebei, Suzhou in Jiangsu,…
-
Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use
•
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced that its subsidiary Legend Biotech Corporation’s (NASDAQ: LEGN) BCMA-targeted chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), has received a recommendation from the US FDA’s Oncologic Drugs Advisory Committee (ODAC). Following a review…
-
Madrigal Pharmaceuticals’ Rezdiffra Earns FDA Accelerated Approval for NASH in Adults
•
The US Food and Drug Administration (FDA) has granted an accelerated approval to Madrigal Pharmaceuticals’ (NASDAQ: MDGL) Rezdiffra (resmetirom) for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) in adults with moderate-to-advanced liver fibrosis. This marks the first approval in the US for a therapy indicated for liver scarring due to…
-
China Aims to Insure 80% of Newborns with Basic Medical Insurance by 2024
•
The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC), along with three other bureaus, have issued a Notice on “Carrying out the Special Action for Children to Participate in Basic Medical Insurance (BMI)”. The notice outlines an ambitious target to ensure that 80% of newborns in China…
-
China Proposes Market-Oriented Pricing for Innovative Drugs to Boost High-Quality Development
•
The National Healthcare Security Administration (NHSA) has unveiled a draft Notification on “Establishing a Price Formation Mechanism for Newly Listed Chemical Drugs to Encourage High-Quality Innovation.” The document, currently open for feedback from industry associations, outlines a proposed framework that aims to balance market determination of drug prices with government…
-
NHSA Launches Service Specifications for Medical Procurement Platform
•
The National Healthcare Security Administration (NHSA) has issued the “Service Specification for Medical Centralized Procurement Platform (Version 1.0)”, which came into effect on July 1, 2024. This document, known as the “Regulations”, concentrates on service aspects of the centralized procurement platform, detailing procedures that include enterprise applications, information authentication standards,…
-
China Regulators Chart Steady Path for ‘Huiminbao’ Medical Insurance Schemes
•
The China Banking and Insurance Regulatory Commission (CBIRC) and National Healthcare Security Administration (NHSA) have issued a notification outlining measures to ensure a stable and orderly implementation of urban ‘Huiminbao’ commercial top-up medical insurance schemes. The notice is open for feedback from insurance companies and industry associations nationwide. The document…
-
China’s NHSA Aims to Balance Drug Prices with New Monitoring System by March 2024
•
The National Healthcare Security Administration (NHSA) has issued a notification aimed at fostering inter-provincial price fairness, integrity, transparency, and balance for drugs sharing the same generic names and manufacturers. The initiative involves a comprehensive review and inspection of drugs based on four criteria: generic name, manufacturer, dosage form, and specification.…
-
China’s 2023 NRDL Expands Coverage with 126 New Drugs, Aims for Savings and Accessibility
•
The National Healthcare Security Administration (NHSA) has released the finalized National Reimbursement Drug List (NRDL) for 2023, adding 126 new drugs to the list. The new additions include 21 oncology drugs, 17 COVID-19 treatments, 15 drugs for diabetes, mental illness, and rheumatoid/immune diseases, and 15 rare disease drugs. The NRDL…
-
China’s NHSA Issues Guidelines to Strengthen Medical Pricing and Procurement Credit Ratings
•
The National Healthcare Security Administration (NHSA) has issued a notification concerning medical pricing and tendering and procurement credit ratings, aiming to clarify the responsibilities associated with the management and maintenance of tendering and procurement order ratings. Provincial pharmaceutical procurement institutions are primarily responsible for pricing and tendering and procurement credit…
-
NHSA Completes Expert Review for National Reimbursement Drug List Updates
•
The National Healthcare Security Administration (NHSA) has announced the completion of the expert review stage for drugs under consideration for inclusion in the upcoming update to the National Reimbursement Drug List (NRDL). This marks a significant step forward in the annual process, which determines which medications will be covered by…
-
NHSA Issues Guidelines to Strengthen Medical Insurance Payment Management
•
The National Healthcare Security Administration (NHSA) has released a set of guiding opinions aimed at enhancing the management of medical insurance payment qualification for relevant personnel in designated medical institutions. The new policies are designed to implement supervision over medical service behavior and expenses covered by medical insurance, strengthen the…
-
EU Chamber of Commerce in China Releases Position Paper, Addresses Pharma and Healthcare
•
The EU Chamber of Commerce in China has released its bi-annual “European Business in China Position Paper 2023/2024,” which compiles recommendations from over 1,700 member companies. The document aims to foster constructive dialogue between Europe and China, enhancing engagement between European firms and Chinese stakeholders for mutual benefit. The paper…
-
NHSA Clears Retagliptin and Ambroxol for National Reimbursement Drug List Inclusion
•
The National Healthcare Security Administration (NHSA) has completed a review of the National Reimbursement Drug List (NRDL) adjustment formality review results for retagliptin and ambroxol. Both drugs, first approved for marketing in China in June 2023 and July 2019 respectively, have been deemed eligible for the filing requirement stipulating “new…
-
NHSA Unveils Measures to Enhance Smart Monitoring and Auditing of Basic Medical Insurance Funds
•
The National Healthcare Security Administration (NHSA) has released a notification detailing planned measures to improve the smart monitoring and auditing of Basic Medical Insurance (BMI) funds. The initiative focuses on addressing disparities in the implementation of the national 1.0 version smart monitoring and auditing system and building upon the existing…
-
NHSA Mandates National Standards for Medical Consumables in Basic Medical Insurance
•
The National Healthcare Security Administration (NHSA) has released a notification with a focus on enhancing the standards for managing Basic Medical Insurance (BMI) payments for medical consumables. The notice indicates a further push towards the adoption of national BMI product codes to ensure uniformity across the country. Expanding BMI Payment…
-
China Releases Third List of Pediatric Drugs to Guide Development and Filings
•
The National Health Commission (NHC), National Healthcare Security Administration, National Medical Products Administration (NMPA), and two additional ministries have released a third list of pediatric drugs aimed at encouraging and guiding drug developers in product development and filings. The list includes a total of 24 varieties, involving 30 specifications and…
